Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 9 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Guusje van SchaickCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.ORCID 0000-0001-8320-4460
Nadi El HajjoutiCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-4729-1488
Simone NicolardiCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
Joost den HartogCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Romana JansenCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Rob van der HoevenCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Wim BijleveldCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Nicolas AbelloCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Manfred WuhrerCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.ORCID 0000-0002-0814-4995
Maurien M A OlsthoornCenter for Analytical Innovation, DSM, Alexander Fleminglaan 1, 2613 AX Delft, The Netherlands.
Elena Domínguez-VegaCenter for Proteomics and Metabolomics, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
DSM (Netherlands) · NLLeiden University Medical Center · NL
Funding
Dutch Research Council 731.017.202
6 · The paper itself
Abstract
Xylanases are of great value in various industries, including paper, food, and biorefinery. Due to their biotechnological production, these enzymes can contain a variety of post-translational modifications, which may have a profound effect on protein function. Understanding the structure-function relationship can guide the development of products with optimal performance. We have developed a workflow for the structural and functional characterization of an endo-1,4-β-xylanase (ENDO-I) produced by
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Native Liquid Chromatography and Mass Spectrometry to Structurally and Functionally Characterize Endo-Xylanase Proteoforms. · full record | OpenQuestion